Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

By Pearl Steinzor

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

By Pearl Steinzor

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com

Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

By Rose McNulty

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

February 19th 2020

Lessons From the Front: Designing and Implementing Clinical Pathways by and for Clinicians

David M. Jackman, MD Joanna Hamilton, MA, MS Emily Foster, MPH Craig A. Bunnell, MD, MPH, MBA Louis Culot, MA Carole Tremonti, RN, MBA Joseph O. Jacobson, MD, MSc

As cancer care becomes more complex and more expensive, decision-support algorithms offer a mechanism to define best practice, reduce unwarranted variation, and control costs across growing networks.

February 8th 2020

This Week in Managed Care: February 7, 2020

This week, top managed care stories included survey results on oncology practices’ willingness to take on risk; a warning of flu among children in detention centers; study findings establishing a link between circadian rhythm and type 2 diabetes.

February 6th 2020

Dr Joshua Ofman: Improving Survival, Reducing Costs in Oncology Vital to Value-Based Care Transition

From a value-based medicine perspective, we think there's no greater value in the healthcare system than improving survival for cancer patients and reducing the costs of treating late stage cancer; we believe the GRAIL test could be the test case for how to make this transition, said Joshua Ofman, MD, MSHS, chief of Corporate Strategy and External Affairs at GRAIL Inc.

February 5th 2020

A Population-Based Assessment of Proton Beam Therapy Utilization in California

Arti Parikh-Patel, PhD, MPH Cyllene R. Morris, DVM, PhD Frances B. Maguire, PhD, MPH Megan E. Daly, MD Kenneth W. Kizer, MD, MPH

This population-based analysis of patients with cancer in California found significant differences in proton beam therapy use by health insurance type, race/ethnicity, and socioeconomic status.

January 28th 2020

American Oncology Network, LLC, Names Todd Schonherz President and Chief Operating Officer

Schonherz will be responsible for day-to-day operations.

January 28th 2020

CMS Agrees to Cover NGS for Medicare Patients With Breast, Ovarian, Other Cancers

Allison Inserro Mary Caffrey

CMS said it is expanding coverage of next generation sequencing (NGS) for use as a diagnostic for patients with germline breast and ovarian cancer, paving the way for Medicare beneficiaries to receive more personalized medicine. However, an advocate said the wording of CMS' decision could actually limit testing access for some women with breast or ovarian cancer.

January 21st 2020

Bundled Payments: Looking Back, Looking Ahead

Alyssa Dahl, MPH

January 17th 2020

Jennifer Atkins Explains How Blue Cross Blue Shield Evaluates Emerging Innovations in Cancer Care

Blue Cross Blue Shield utilizes data to drive insights into what works and what doesn't work in cancer care, as well as, delineating trends through our collaboration with provider specialties and organizations across the US, said Jennifer Atkins, MBA, vice president of Network Solutions at Blue Cross Blue Shield.

January 4th 2020

When Less Is More: Halving Chemo Keeps Testicular Cancer at Bay, Study Finds

Mary Caffrey

Testicular cancer is the most common cancer to be diagnosed in men as younger men—those younger than age 40—and it can be particularly aggressive. Advances in therapy have improved survival rates, but if young men have chemotherapy after surgery, they may live with side effects for decades.

January 2nd 2020

What We're Reading: Healthcare Issues to Watch; e-Cig Flavor Ban; Google AI and Breast Cancer

AJMC Staff

Five issues in healthcare were spotlighted as key developments to watch; FDA to ban all e-cig vape flavors except for menthol and tobacco; Google AI system shown to improve detection of breast cancer through mammograms.

December 27th 2019

An Immune-Suppressing Target for Glioblastoma?

Mary Caffrey

A team at The University of Texas MD Anderson Cancer Center in Houston led by original pioneers in immuno-oncology have published a paper in Nature Medicine that discusses an immune-suppressing enzyme that was strongly present in glioblastoma but not in 5 other tumor types the team studied.

December 19th 2019

Improving Survival in Lung Cancer: Commitment of The Lung Ambition Alliance

Giorgio Scagliotti, MD, PhD

For more than 45 years, the International Association for the Study of Lung Cancer has been working tirelessly toward a world without lung and other thoracic cancers. To add strength to our efforts we recently joined with other leading organizations in the lung cancer space to create a powerful force for change: The Lung Ambition Alliance

December 19th 2019

Future of BCC and CSCC Therapy

December 19th 2019

Second-Line Systemic Treatment of BCC

December 19th 2019

Systemic Therapy in BCC

December 19th 2019

Electing for Surgery in the Management of BCC

December 19th 2019

Overview of Basal Cell Carcinoma

December 19th 2019

Toxicity Profile and Pseudoprogression

December 19th 2019

PD-1 and Other Systemic Treatment Options for CSCC

December 19th 2019

Using Immunotherapy in CSCC

December 19th 2019

Systemic Treatment of CSCC

December 19th 2019

Standard of Care for CSCC

December 19th 2019

Overview of Cutaneous Squamous Cell Carcinoma

December 18th 2019

Radiation Oncologist Discusses Concerns With Incoming CMS Payment Model

Allison Inserro

As CMS prepares to move forward with new models of value-based cancer care, a radiation oncologist, speaking at the Institute for Value-Based Medicine®, discussed her findings regarding whether accountable care models had an effect on cancer care spending.

December 18th 2019

Hope and Some Skepticism Whether Oncology Payment Models Will Work

Allison Inserro

Coverage from the Institute for Value-Based Medicine® session held in Nashville, Tennessee.

December 18th 2019

Risk of Heart Failure Greater in Patients With AML, ALL on Anthracyclines

Maggie L. Shaw

In cases of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), there is a greater risk of symptomatic heart failure in the first year following initiation of anthracycline treatment.

December 17th 2019

Government-Insured Patients With Breast Cancer Face a Higher Risk of Death

Gianna Melillo

Patients with breast cancer who have government insurance face a higher risk of death, according to a retrospective study presented at the 2019 San Antonio Breast Cancer Symposium on December 13.

December 17th 2019

From the Editor-in-Chief: Lead, Follow, or Get Out of the Way

Joseph Alvarnas, MD

Dr Alvarnas is editor-in-chief of Evidence-Based Oncology.™ He is vice president of Government Affairs, senior medical director for Employer Strategy, and associate clinical professor, Hematology & Hematologic Cell Transplantation, City of Hope, Duarte, Califonia.

December 16th 2019

Provider Perspective: Stephen M. Schleicher, MD, MBA, Addresses Accountability Versus Control in Oncology Care First

Mary Caffrey

An article Schleicher co-wrote in JAMA Oncology, which appeared the day before the announcement of Oncology Care First, offered insights into the need for changes to the original OCM.

December 16th 2019

Provider Perspective: Kashyap Patel, MD, Sees Collaboration Going Into Oncology Care First

Mary Caffrey

Kashyap Patel, MD, the chief executive officer of Carolina Blood and Cancer Care Associates—a leading OCM practice—and associate editor of Evidence-Based Oncology™ (EBO), said he’s optimistic about Oncology Care First.

...

18 19 20 21 22 23 24 25 26

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions